AngioDynamics, Inc. (FRA:UG2)

Germany flag Germany · Delayed Price · Currency is EUR
9.35
-0.40 (-4.10%)
At close: Mar 27, 2026
Market Cap389.97M +14.8%
Revenue (ttm)265.02M +7.3%
Net Income-23.90M
EPS-0.58
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume30
Open9.80
Previous Close9.75
Day's Range9.30 - 9.80
52-Week Range7.00 - 13.20
Betan/a
RSI51.32
Earnings DateApr 2, 2026

About AngioDynamics

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device tha... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 1988
Employees 675
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol UG2

Financial Performance

In fiscal year 2025, AngioDynamics's revenue was $292.50 million, a decrease of -3.76% compared to the previous year's $303.91 million. Losses were -$33.99 million, -81.56% less than in 2024.

Financial numbers in USD Financial Statements

News

AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

10 days ago - Business Wire

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

4 weeks ago - Business Wire

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

5 weeks ago - Business Wire

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

7 weeks ago - Business Wire

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...

7 weeks ago - Business Wire

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2 months ago - Seeking Alpha

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

2 months ago - Seeking Alpha

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

2 months ago - Business Wire

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

AngioDynamics, Inc. (NASDAQ: ANGO) will release earnings results for its second quarter before the opening bell on Tuesday, Jan. 6, 2026.

3 months ago - Benzinga

AngioDynamics: Growth Remains Under The Radar

AngioDynamics looks undervalued, with Med Tech segment growth in thrombus management, atherectomy, and NanoKnife driving the investment thesis. Consistent execution on revenue growth and margin improv...

3 months ago - Seeking Alpha

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 months ago - Business Wire

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...

3 months ago - Business Wire

AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

AngioDynamics, Inc. ( ANGO) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO ...

4 months ago - Seeking Alpha

AngioDynamics to Participate in the UBS Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...

5 months ago - Business Wire

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...

5 months ago - Business Wire

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong perform...

6 months ago - Seeking Alpha

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference C...

6 months ago - Seeking Alpha

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.

6 months ago - Benzinga

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

6 months ago - Business Wire

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 2.

6 months ago - Benzinga

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

6 months ago - Business Wire

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results con...

8 months ago - Seeking Alpha

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

8 months ago - Business Wire

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...

8 months ago - Business Wire

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

8 months ago - Business Wire